MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage

Amplification of the MYC proto-oncogene is frequently observed in various cancer types, including triple-negative breast cancer (TNBC). Emerging evidence suggests that suppression of local antitumor immune responses by MYC, at least in part, explains the tumor-promoting effects of MYC. Specifically,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of biological chemistry Jg. 301; H. 6; S. 108560
Hauptverfasser:	Linstra, Renske, Stappenbelt, Chantal, Bakker, Femke J., Everts, Marieke, Bhattacharya, Arkajyoti, Yu, Shibo, van Bergen, Stella D., van der Vegt, Bert, Wisman, G. Bea A., Fehrmann, Rudolf S.N., de Bruyn, Marco, van Vugt, Marcel A.T.M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.06.2025 American Society for Biochemistry and Molecular Biology
Schlagworte:	breast cancer Cell Line, Tumor DNA Damage Down-Regulation Female Gene Expression Regulation, Neoplastic Humans Inflammation - genetics Inflammation - metabolism innate immunity interferon Membrane Proteins - genetics Membrane Proteins - metabolism Myc (c-MYC) Proto-Oncogene Mas Proto-Oncogene Proteins c-myc - genetics Proto-Oncogene Proteins c-myc - metabolism Signal Transduction STAT1 Transcription Factor - genetics STAT1 Transcription Factor - metabolism STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism transcription regulation Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - immunology Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology tumor immunology transcription regulation tumor immunology HRP breast cancer interferon ChIP Dox PBMC IFN innate immunity FCS cGAS MCP-counter STING cDNA TNBC METABRIC Myc (c-MYC) ISRE
ISSN:	0021-9258, 1083-351X, 1083-351X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!